Shuttle Pharma Appoints New CMO, Elects New Director
Ticker: SHPH · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, appointment, director-departure
TL;DR
Shuttle Pharma brings in new CMO/Director David Epstein, while Dr. van der Laan departs.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. announced on July 24, 2025, a series of significant corporate actions. These include the departure of Director Dr. Robert L. J. van der Laan, the election of Dr. David M. Epstein as a new director, and the appointment of Dr. Epstein as Chief Medical Officer. Additionally, the company entered into a new employment agreement with Dr. Epstein.
Why It Matters
The appointment of a new Chief Medical Officer and director signals a potential shift in the company's strategic direction and leadership, which could impact its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership and the appointment of a new Chief Medical Officer can introduce uncertainty regarding the company's strategic direction and operational execution.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- Dr. Robert L. J. van der Laan (person) — Departing Director
- Dr. David M. Epstein (person) — Newly Elected Director and Chief Medical Officer
- July 24, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from the Board of Directors?
Dr. Robert L. J. van der Laan has departed from the Board of Directors.
Who has been elected as a new director?
Dr. David M. Epstein has been elected as a new director.
What new role has Dr. David M. Epstein taken on?
Dr. David M. Epstein has been appointed as the Chief Medical Officer.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 24, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 by Dr. Robert L. J. van der Laan regarding Shuttle Pharmaceuticals Holdings, Inc. (SHPH).